1.Advances of mechanical conditions in engineering cartilage tissue
Chunqiu ZHANG ; Minlin SUN ; Jiang LI ; Jinduo YE ; Haiying LIU
Journal of Medical Biomechanics 2009;24(6):462-467
There are many physical factors affecting the development of cartilage tissue,the mechanical con-dition is the main important one that particularly act.The mechanical conditions used in engineering cartilage tissue,such as compressive and shear force,fluid flow,hydrostatic pressure and tissue deformation or with some of them combined,were reviewed.From the standpoint of bionics,the mechanical environments ap-plied on tissue engineering should work in three aspects:providing adequately mechanical stimuli to the cells seeded in 3-D scaffold;ensuring the efficient mass-transport of the nutrients and waste products in the cells:promoting the development of functionally extracellular matrix in 3-D scaffold.The mechanical environments currently used only represented the part of mechanical conditions of in vive articular cartilage will be reviewed.In our view that rolling depression load may achieve the fit mechanical environment for cultivation of functional cartilage constructs in vitro.
2.Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.
Minlin JIANG ; Keyi JIA ; Lei WANG ; Wei LI ; Bin CHEN ; Yu LIU ; Hao WANG ; Sha ZHAO ; Yayi HE ; Caicun ZHOU
Acta Pharmaceutica Sinica B 2021;11(10):2983-2994
Genomic instability remains an enabling feature of cancer and promotes malignant transformation. Alterations of DNA damage response (DDR) pathways allow genomic instability, generate neoantigens, upregulate the expression of programmed death ligand 1 (PD-L1) and interact with signaling such as cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling. Here, we review the basic knowledge of DDR pathways, mechanisms of genomic instability induced by DDR alterations, impacts of DDR alterations on immune system, and the potential applications of DDR alterations as biomarkers and therapeutic targets in cancer immunotherapy.